Dianthus Therapeutics, Inc. /DE/ Cash and Cash Equivalents, Period Increase (Decrease)
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Cash and Cash Equivalents, Period Increase (Decrease) of $108.27 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-08.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-11-08
- Dianthus Therapeutics, Inc. /DE/ cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was -$13.76M.
- Dianthus Therapeutics, Inc. /DE/ cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was -$3.83M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month |
|---|---|---|---|
| 2018-09-30 | -$13.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $108.27M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $122.03M 10-Q · filed 2018-08-09 | ||
| 2017-09-30 | -$3.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $55.44M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $59.27M 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |